E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with Hepatocellular carcinoma not amenable to curative treatment |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with Hepatocellular carcinoma not amenable to curative treatment |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10029104 |
E.1.2 | Term | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10007416 |
E.1.2 | Term | Carcinoma liver |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10019828 |
E.1.2 | Term | Hepatocellular carcinoma non-resectable |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Determination of the progression free survival (PFS) time |
|
E.2.2 | Secondary objectives of the trial |
Determination of – overall survival (OS) – response/disease control rate (DCR) (either complete response, CR, or partial response, as measured by mRECIST for HCC) – time to progression – time to macrovascular invasion/extrahepatic spread (MVI/EHS) – time to unTACEable progression – safety profile – quality of life (as measured by FACT-Hep and FACT-G7 questionnaires)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Written informed consent granted prior to initiation of any study specific screening procedures 2. Patients with histologically confirmed HCC primarily not suitable for resection, ablation or liver transplantation. A combined therapy with TACE and subsequent ablation is possible. 3. Availability of Biopsy for translational research, if patients give their consent 4. Absence of extrahepatic spread 5. Age >/= 18 years 6. Patients with measurable disease according to mRECIST 7. Performance status ECOG 0 and 1 (Appendix 20) 8. Normal organ and bone marrow function defined as: – Hematopoetic: absolute neutrophil count ≥ 1,500/mm3, platelet count ≥ 60 x 109/l, hemoglobin ≥ 9 g/dL – INR ≤ 1.5 x ULN – Hepatic: AST and ALT < 5 x ULN, bilirubin ≤ 2 mg/dl – Renal: serum creatinine ≤ 1.5 x ULN 9. Child-Pugh stage A 10. Women of childbearing potential must have a negative pregnancy test performed within 7 days prior to enrolment 11. Male or female patients of child-bearing potential must agree to use oral contraception, intrauterine device, bilateral tubal occlusion, vasectomized partner or avoidance of intercourse during the study and for 180 days after last investigational drug dose received
|
|
E.4 | Principal exclusion criteria |
1. Extrahepatic tumor manifestation 2. Tumor infiltration of more than 50% of the whole liver mass 3. Infiltration or thrombosis of the main portal vein or the main left or right intrahepatic branches 4. Child Pugh status B or C > 6 points according to Child Pugh classification (Appendix 20) 5. Prior TACE or selective intraarterial Radiotherapy (SIRT) 6. Prior systemic anticancer therapy for HCC 7. Life expectancy of less than 12 weeks 8. Esophageal varices grade III (any) or esophageal varices grade II with increased risk for bleeding (red wale signs, cherry spots, red coloration, hematocystic spots) without prophylactic band ligation 9. Known or suspected manifest hyperthyroidism 10. Congestive heart failure > class II NYHA (Appendix 20) 11. Cardiac ventricular arrhythmias requiring antiarrhythmic therapy, acute myocardial infarction, myocardial infarction, acute inflammatory heart disease > CTCAE grade 2 within the past 6 months (Appendix 20) 12. Previous treatment with doxorubicin up to the maximum lifetime dose of 550mg/m2 13. History of organ allograft or bone marrow transplantation 14. Active uncontrolled clinically serious infections > CTCAE grade 2 except chronic hepatitis C infection (Appendix 20) 15. Severe restrictive or obstructive lung disease 16. Clinically apparent chronic inflammatory bowel disease and/or ileus 17. Hemorrhage/bleeding event or variceal bleeding > CTCAE grade 2 within 4 weeks of first dose of study drug (Appendix 20) 18. Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug 19. Known or suspected allergies to Iodine-containing or Gadolinum-containing contrast medium, Irinotecan, Mitomycin C, Doxorubicin or other inactive ingredients of the drugs 20. Previous cancer that is distinct in primary site or histology from HCC except cervical cancer in situ, treated basal cell carcinoma, superficial bladder tumors or any cancer curatively treated 3 years prior to study entry 21. Concomitant treatment with St. John's wort 22. Substance abuse, medical, psychological or social condition that may interfere with the patient´s participation in the study 23. Participation in another clinical trial with any investigational study drug (whatever the use, curative, prophylactic or diagnostic intent) within 30 days prior to enrollment 24. Incapability to give valid informed consent (including patients who are dependent on the sponsor or the investigator) 25. Pregnancy or breast-feeding women
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Progression free survival (PFS) time |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
– overall survival (OS) – response/disease control rate (DCR) (either complete response, CR, or partial response, as measured by mRECIST for HCC) – time to progression – time to macrovascular invasion/extrahepatic spread (MVI/EHS) – time to unTACEable progression – safety profile – quality of life (as measured by FACT-Hep and FACT-G7 questionnaires) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Database closure is defined as the end of the trial: Sites need to collect survival data of patients and are involved in the data cleaning process actively (e.g. additional source data may be requested and additonal monitoring visits may be neccessary). Therefore, database closure is considered the end of the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |